{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T20:46:21Z","timestamp":1792010781658,"version":"4.4.0"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["20K09518"],"award-info":[{"award-number":["20K09518"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000646","name":"Japan Society for the Promotion of Science London","doi-asserted-by":"publisher","award":["24K19645"],"award-info":[{"award-number":["24K19645"]}],"id":[{"id":"10.13039\/501100000646","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008672","name":"Yamaguchi Endocrine Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008672","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["P01CA163227"],"award-info":[{"award-number":["P01CA163227"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["P50CA272390"],"award-info":[{"award-number":["P50CA272390"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005865","name":"Mochida Memorial Foundation for Medical and Pharmaceutical Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.canlet.2026.218895","type":"journal-article","created":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T07:00:29Z","timestamp":1791874829000},"page":"218895","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Acute MCL1 Loss via Homoharringtonine-Mediated Translational Inhibition Enables Potent Apoptotic Synergy with BCLXL Blockade"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-4757-4633","authenticated-orcid":false,"given":"Akira","family":"Ohtsu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuhiro","family":"Sawada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larysa","family":"Poluben","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mai","family":"Onose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayumi","family":"Oyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayaka","family":"Katayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Betul","family":"Ersoy-Fazlioglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan M.","family":"Jim\u00e9nez-Vacas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Otani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8416-2394","authenticated-orcid":false,"given":"Yoshiyuki","family":"Miyazawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshitaka","family":"Sekine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuta","family":"Maeno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takanori","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8941-161X","authenticated-orcid":false,"given":"Tsukasa","family":"Oda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaoyong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Voznesensky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2558-0203","authenticated-orcid":false,"given":"Xin","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-4362-9892","authenticated-orcid":false,"given":"Luigi Giovanni","family":"Cecchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6043-4789","authenticated-orcid":false,"given":"Robert A.","family":"Cerulli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motohiro","family":"Izumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-1099-9152","authenticated-orcid":false,"given":"Ikei S.","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuo","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2262-4001","authenticated-orcid":false,"given":"Susumu S.","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4546-7371","authenticated-orcid":false,"given":"Steven P.","family":"Balk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9514-735X","authenticated-orcid":false,"given":"Seiji","family":"Arai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"15","key":"10.1016\/j.canlet.2026.218895_bib1","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1056\/NEJMoa040720","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer","volume":"351","author":"Tannock","year":"2004","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.canlet.2026.218895_bib2","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa041318","article-title":"Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer","volume":"351","author":"Petrylak","year":"2004","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.canlet.2026.218895_bib3","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","article-title":"Abiraterone and increased survival in metastatic prostate cancer","volume":"364","author":"de Bono","year":"2011","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.canlet.2026.218895_bib4","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","article-title":"Increased survival with enzalutamide in prostate cancer after chemotherapy","volume":"367","author":"Scher","year":"2012","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.canlet.2026.218895_bib5","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa1209096","article-title":"Abiraterone in metastatic prostate cancer without previous chemotherapy","volume":"368","author":"Ryan","year":"2013","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.canlet.2026.218895_bib6","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1056\/NEJMoa1405095","article-title":"Enzalutamide in metastatic prostate cancer before chemotherapy","volume":"371","author":"Beer","year":"2014","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.canlet.2026.218895_bib7","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrm2308","article-title":"The BCL-2 protein family: opposing activities that mediate cell death","volume":"9","author":"Youle","year":"2008","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"1","key":"10.1016\/j.canlet.2026.218895_bib8","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/nrm3722","article-title":"Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy","volume":"15","author":"Czabotar","year":"2014","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"6","key":"10.1016\/j.canlet.2026.218895_bib9","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.ccell.2018.11.004","article-title":"BH3-mimetic drugs: Blazing the trail for new cancer medicines","volume":"34","author":"Merino","year":"2018","journal-title":"Cancer Cell"},{"issue":"12","key":"10.1016\/j.canlet.2026.218895_bib10","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S1470-2045(10)70261-8","article-title":"Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity","volume":"11","author":"Wilson","year":"2010","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.canlet.2026.218895_bib11","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nm.3048","article-title":"ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets","volume":"19","author":"Souers","year":"2013","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.canlet.2026.218895_bib12","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1513257","article-title":"Targeting BCL2 with venetoclax in relapsed chronic Lymphocytic leukemia","volume":"374","author":"Roberts","year":"2016","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.canlet.2026.218895_bib13","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1200\/JCO.2010.31.6208","article-title":"Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors","volume":"29","author":"Gandhi","year":"2011","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.canlet.2026.218895_bib14","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.ccr.2006.08.027","article-title":"The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak\/Bax if Mcl-1 is neutralized","volume":"10","author":"van Delft","year":"2006","journal-title":"Cancer Cell"},{"issue":"7626","key":"10.1016\/j.canlet.2026.218895_bib15","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/nature19830","article-title":"The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models","volume":"538","author":"Kotschy","year":"2016","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.canlet.2026.218895_bib16","doi-asserted-by":"crossref","first-page":"5341","DOI":"10.1038\/s41467-018-07551-w","article-title":"Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia","volume":"9","author":"Tron","year":"2018","journal-title":"Nat Commun"},{"issue":"12","key":"10.1016\/j.canlet.2026.218895_bib17","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1158\/2159-8290.CD-18-0387","article-title":"AMG 176, a selective MCL1 inhibitor, is effective in hematologic cancer models alone and in combination with established therapies","volume":"8","author":"Caenepeel","year":"2018","journal-title":"Cancer Discov"},{"issue":"1","key":"10.1016\/j.canlet.2026.218895_bib18","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s13045-025-01753-8","article-title":"First in human phase 1 study of DT2216, a selective BCL-xL degrader, in patients with relapsed\/refractory solid malignancies","volume":"18","author":"Mahadevan","year":"2025","journal-title":"J Hematol Oncol"},{"issue":"5","key":"10.1016\/j.canlet.2026.218895_bib19","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.ccr.2006.03.027","article-title":"Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members","volume":"9","author":"Certo","year":"2006","journal-title":"Cancer Cell"},{"issue":"2","key":"10.1016\/j.canlet.2026.218895_bib20","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.ccr.2007.07.001","article-title":"BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents","volume":"12","author":"Deng","year":"2007","journal-title":"Cancer Cell"},{"issue":"11","key":"10.1016\/j.canlet.2026.218895_bib21","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1101\/gad.1304105","article-title":"Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins","volume":"19","author":"Willis","year":"2005","journal-title":"Genes Dev"},{"issue":"21","key":"10.1016\/j.canlet.2026.218895_bib22","doi-asserted-by":"crossref","first-page":"5458","DOI":"10.1158\/1078-0432.CCR-18-0549","article-title":"Tyrosine kinase inhibitors increase MCL1 degradation and in combination with BCLXL\/BCL2 inhibitors drive prostate cancer apoptosis","volume":"24","author":"Arai","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"10","key":"10.1016\/j.canlet.2026.218895_bib23","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.15252\/embr.201642195","article-title":"The integrated stress response","volume":"17","author":"Pakos-Zebrucka","year":"2016","journal-title":"EMBO Rep"},{"key":"10.1016\/j.canlet.2026.218895_bib24","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.54954","article-title":"MARCH5 mediates NOXA-dependent MCL1 degradation driven by kinase inhibitors and integrated stress response activation","volume":"9","author":"Arai","year":"2020","journal-title":"Elife"},{"issue":"8","key":"10.1016\/j.canlet.2026.218895_bib25","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1038\/s41418-020-0503-6","article-title":"MARCH5-dependent degradation of MCL1\/NOXA complexes defines susceptibility to antimitotic drug treatment","volume":"27","author":"Haschka","year":"2020","journal-title":"Cell Death Differ"},{"issue":"10","key":"10.1016\/j.canlet.2026.218895_bib26","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1021\/acsmedchemlett.9b00568","article-title":"Discovery of A-1331852, a first-in-class, potent, and orally-bioavailable BCL-XL inhibitor","volume":"11","author":"Wang","year":"2020","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.canlet.2026.218895_bib27","doi-asserted-by":"crossref","first-page":"4749","DOI":"10.2147\/DDDT.S279054","article-title":"Homoharringtonine exerts an antimyeloma effect by promoting excess Parkin-dependent mitophagy","volume":"14","author":"Zhang","year":"2020","journal-title":"Drug Des Devel Ther"},{"issue":"115875","key":"10.1016\/j.canlet.2026.218895_bib28","article-title":"Mitochondrial complex I inhibition by homoharringtonine: A novel strategy for suppression of chronic myeloid leukemia","volume":"218","author":"Han","year":"2023","journal-title":"Biochem Pharmacol"},{"issue":"7","key":"10.1016\/j.canlet.2026.218895_bib29","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1158\/1078-0432.CCR-13-1283","article-title":"Omacetaxine: a protein translation inhibitor for treatment of chronic myelogenous leukemia","volume":"20","author":"Gandhi","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.canlet.2026.218895_bib30","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1634\/theoncologist.2013-0077","article-title":"U.S. Food and Drug Administration approval summary: omacetaxine mepesuccinate as treatment for chronic myeloid leukemia","volume":"19","author":"Alvandi","year":"2014","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.canlet.2026.218895_bib31","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.jmb.2009.04.005","article-title":"U2504 determines the species specificity of the A-site cleft antibiotics: the structures of tiamulin, homoharringtonine, and bruceantin bound to the ribosome","volume":"389","author":"G\u00fcrel","year":"2009","journal-title":"J Mol Biol"},{"issue":"1","key":"10.1016\/j.canlet.2026.218895_bib32","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1182\/blood-2010-01-262808","article-title":"Homoharringtonine reduced Mcl-1 expression and induced apoptosis in chronic lymphocytic leukemia","volume":"117","author":"Chen","year":"2011","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.canlet.2026.218895_bib33","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2012.149","article-title":"Translation inhibitors induce cell death by multiple mechanisms and Mcl-1 reduction is only a minor contributor","volume":"3","author":"Lindqvist","year":"2012","journal-title":"Cell Death Dis"},{"issue":"5","key":"10.1016\/j.canlet.2026.218895_bib34","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1158\/1078-0432.CCR-15-1191","article-title":"Targeting of BCL2 family proteins with ABT-199 and homoharringtonine reveals BCL2- and MCL1-dependent subgroups of diffuse large B-cell lymphoma","volume":"22","author":"Klanova","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.canlet.2026.218895_bib35","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1124\/mol.110.068528","article-title":"Bcl-xL is a dominant antiapoptotic protein that inhibits homoharringtonine-induced apoptosis in leukemia cells","volume":"79","author":"Yin","year":"2011","journal-title":"Mol Pharmacol"},{"issue":"2","key":"10.1016\/j.canlet.2026.218895_bib36","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/j.1365-2141.2007.06899.x","article-title":"ABT-737 is a useful component of combinatory chemotherapies for chronic myeloid leukaemias with diverse drug-resistance mechanisms","volume":"140","author":"Kuroda","year":"2008","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.canlet.2026.218895_bib37","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.gpb.2022.01.004","article-title":"SynergyFinder plus: Toward better interpretation and annotation of drug combination screening datasets","volume":"20","author":"Zheng","year":"2022","journal-title":"Genomics Proteomics Bioinformatics"},{"issue":"D1","key":"10.1016\/j.canlet.2026.218895_bib38","doi-asserted-by":"crossref","first-page":"D1541","DOI":"10.1093\/nar\/gkaa1011","article-title":"MitoCarta3.0: an updated mitochondrial proteome now with sub-organelle localization and pathway annotations","volume":"49","author":"Rath","year":"2021","journal-title":"Nucleic Acids Res"},{"issue":"22","key":"10.1016\/j.canlet.2026.218895_bib39","doi-asserted-by":"crossref","first-page":"4722","DOI":"10.1016\/j.molcel.2021.09.015","article-title":"Proteome-wide mapping of short-lived proteins in human cells","volume":"81","author":"Li","year":"2021","journal-title":"Mol Cell"},{"key":"10.1016\/j.canlet.2026.218895_bib40","unstructured":"Team RC. R: A language and environment for statistical computing [Internet]. Available from: https:\/\/www.R-project.org"},{"issue":"2","key":"10.1016\/j.canlet.2026.218895_bib41","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1083\/jcb.200809153","article-title":"Bax activation by the BH3-only protein Puma promotes cell dependence on antiapoptotic Bcl-2 family members","volume":"185","author":"Gallenne","year":"2009","journal-title":"J Cell Biol"},{"issue":"3","key":"10.1016\/j.canlet.2026.218895_bib42","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1158\/1078-0432.CCR-20-2246","article-title":"Exploiting protein translation dependence in multiple myeloma with omacetaxine-based therapy","volume":"27","author":"Walker","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"14","key":"10.1016\/j.canlet.2026.218895_bib43","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adm7098","article-title":"Identification of an anaplastic subtype of prostate cancer amenable to therapies targeting SP1 or translation elongation","volume":"10","author":"Zou","year":"2024","journal-title":"Sci Adv"},{"issue":"5","key":"10.1016\/j.canlet.2026.218895_bib44","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.ccell.2023.03.021","article-title":"Transcriptional-translational conflict is a barrier to cellular transformation and cancer progression","volume":"41","author":"Jana","year":"2023","journal-title":"Cancer Cell"},{"issue":"12","key":"10.1016\/j.canlet.2026.218895_bib45","doi-asserted-by":"crossref","first-page":"2980","DOI":"10.1016\/j.bbamcr.2013.08.006","article-title":"Simultaneous knock-down of Bcl-xL and Mcl-1 induces apoptosis through Bax activation in pancreatic cancer cells","volume":"1833","author":"Takahashi","year":"2013","journal-title":"Biochim Biophys Acta"},{"issue":"1","key":"10.1016\/j.canlet.2026.218895_bib46","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1186\/s12916-021-02158-3","article-title":"Functional apoptosis profiling identifies MCL-1 and BCL-xL as prognostic markers and therapeutic targets in advanced thymomas and thymic carcinomas","volume":"19","author":"M\u00fcller","year":"2021","journal-title":"BMC Med"},{"issue":"9","key":"10.1016\/j.canlet.2026.218895_bib47","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.1158\/0008-5472.CAN-07-5836","article-title":"ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor","volume":"68","author":"Tse","year":"2008","journal-title":"Cancer Res"}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383526006592?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383526006592?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T20:04:44Z","timestamp":1792008284000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383526006592"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":47,"alternative-id":["S0304383526006592"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2026.218895","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Acute MCL1 Loss via Homoharringtonine-Mediated Translational Inhibition Enables Potent Apoptotic Synergy with BCLXL Blockade","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2026.218895","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"218895"}}